Laboratory Dilutions of Thioridaxine with Potential to Enhance Antibiotic Sensitivity in a Multidrug Resistant Escherichia Coli Uropathogen
Science Journal of Clinical Medicine
Volume 4, Issue 2, March 2015, Pages: 32-40
Received: Dec. 14, 2014; Accepted: Dec. 29, 2014; Published: Mar. 9, 2015
Views 2956      Downloads 112
Authors
Otajevwo F. D., Dept. of Microbiology & Biotechnology, Western Delta University, Oghara, Nigeria
Iyabor F. O., Dept. of Microbiology & Biotechnology, Western Delta University, Oghara, Nigeria
Article Tools
Follow on us
Abstract
This research effort seeks to use doses of thioridaxine to enhance antibiotic sensitivity in a MDR Escherichia coli strain. Five axenic (pure) strains of Escherichia coli coded EC1 to EC5 were obtained from five infected midstream urine samples among several other urine samples inoculated on sterile Cystine Lactose Electrolyte Deficient (CLED) agar with appropriate labeling in the Microbiology and Biotechnology Laboratory of Western Delta University, Oghara, Nigeria and stocked on sterile Nutrient agar slants at 4oC in a refrigerator. Slant cultures were sub-cultured aseptically on fresh sterile CLED agar plates and incubated aerobically at 37oC for 24hrs to confirm Escherichia coli strains. Gram staining, indole production, methyl red test, voges praskaeur and citrate utilization tests were done on the resulting colonies to further confirm the strains as E.coli. Antibiotic susceptibility test was done by agar disc diffusion method on all confirmed strains on sterile Mueller- Hinton agar plates before and after treatment with laboratory dilutions of thioridaxine. Only E.coli strain 2 (EC2) was multidrug resistant as it resisted 4(44.4%) of the antibiotics used which were cefuroxime, nalidixic acid, augmentin and tetracycline. Other strains resisted 1-2 antibiotics. The highest (15.6±20.6mm) and least (2.0±8.1mm) zones of inhibition by all five strains were recorded for ofloxacin and cefuroxime respectively. Whereas all five uropathogen strains resisted augmentin, they were sensitive to ciprofloxacin, ofloxacin (both being fluoroquinolones), gentamicin, chloramphenicol and nitrofurantoin. After treatment with 2000-2240ug/ml laboratory dilutions of thioridaxine, ≤50.0% loss of resistance was recorded for 2040ug/ml, 2160ug/ml and 2240ug/ml dilutions. Thioridaxine dilution of 2040ug/ml induced 250% and 90% resistance losses of EC2 to ciprofloxacin and nitrofurantoin respectively with an overall mean±S.E loss of 68.0±24.4%. Resistance losses of 112.5%, 130.0% and 100.0% to ciprofloxacin, nitrofurantoin and chloramphenicol respectively were recorded after 2160ug/ml treatment and 68.5±16.3% overall loss of resistance. Thioridaxine dilutions of 2240ug/ml induced 55.6±25.0% overall loss of resistance with a corresponding 50.0%, 50.0%, 58.1%, 70.0% and 50.0% resistance losses with gentamicin, ciprofloxacin, ofloxacin, nitrofurantoin and chloramphenicol respectively. Less than 50% resistance losses were recorded for 2000, 2080, 2120 and 2200ug/ml dilutions. Minimum inhibitory concentration of chloramphenicol was lowered by 2080ug/ml, 2160ug/ml and 2240ug/ml dilutions by two-fold (15ug), two-fold (15ug) and four-fold (7.5ug) respectively. The medical/ chemotherapeutic implications of these findings are discussed.
Keywords
Invitro, Dilutions, Thioridaxine, Enhance, Antibiotic, Sensitivity, MDR E.coli
To cite this article
Otajevwo F. D., Iyabor F. O., Laboratory Dilutions of Thioridaxine with Potential to Enhance Antibiotic Sensitivity in a Multidrug Resistant Escherichia Coli Uropathogen, Science Journal of Clinical Medicine. Vol. 4, No. 2, 2015, pp. 32-40. doi: 10.11648/j.sjcm.20150402.13
References
[1]
Akhorta, E.E, Aluyi, H.A.S, Enerijiofi, K.E. (2011). Transfer of amoxicillin resistance gene among bacteria isolates from sputum of pneumonia patients attending the University of Benin Teaching Hospital, Benin City, Nigeria. J.Med.Med.Sci.2 (7):1003-1009.
[2]
Akortha, E.E and Filgona, J. (2009). Transfer of gentamicin resistance genes among enterobacteriaceae isolated from the outpatients with urinary tract infections attending 3 hospitals in Mubi, Adamawa State. Scientific Research and essay. 4(8): 745-752.
[3]
Amara, L., Spendler, G., Martins, A and Molnar, J. (2013). Efflux pumps that bestow multidrug resistance of pathogenic gram negative bacteria. Biochem. Pharmacol. Journ. 2(3): 119-121.
[4]
Barth, V.N., Charnet, E., Martin, L.J and Need, A.B. (2006). Comparison of rat dopamine D2 receptor occupancy for a series of anti-psychotic drugs like thioridaxine. Life Science. 78(26): 3007-3019.
[5]
Bauer, A.W, Kirby, W.M.M, Sherris, J.C, Turk, M. (1966). Antibiotic susceptibility testing by a standardized single disc method. Am.J.Clin.Pathol. 45:493-496.
[6]
Bergeron, M.G. (1995). Treatment of pyelonephritis in adults. Med. Clin. N. Am. 75: 619 - 649.
[7]
Byron, F, Brehm, S, Eric, A.J. (2003). Sensitization of Staphylococcus aureus and Escherichia coli to antibiotics by these sesquiterpenoids. Antimicrob. Agents Chemother. 47(10):3357-3360.
[8]
Chakrabarthy, P.K., Mishra, A.K and Chakrabarti, S.K. (1984). Loss of plasmid-like drug resistance after treatment with iodo-deoxyuridine. Indian Journ. Expt. Biol. 22: 333-334.
[9]
Cowan, S.T and Steel, K.J. (1993). Manual for the identification of medical bacteria. 3rd edn. Cambridge University Press. Lonon, New York, Rockville, Melbourne and Sydney. 150p.
[10]
Crowle, A.J, Douvas, S.G, May, M.H. (1992). Chlorpromazine: a drug potentially useful for treating Mycobacterial infections. Chemotherapy. 38:410-419.
[11]
Dimitru, G., Poiata, A., Tuchilus, C and Buiuc, D. (2006). Correlation between linezolid zone diameter and minimum inhibitory concentration valves determined by regression analysis. Rev. Med. Chir. Soc. 110(4): 1016-1025.
[12]
Gupta, T.D., Bandyopathy, T., Dastidar, S.G., Bandopadhyay, M., Mistra, A and Chakrabarty, A.N. (1980). R- plasmids of Staphylococci and their elimination by different agents. Indian Journ. Expt. Biol. 18: 478-481.
[13]
Jan, M.B, John, D.T, Sentry, P. (2002). High prevalence of oxacillin resistant Staph aureus isolates from hospitalized patients in Asia-Pacific and South Africa: Results from SENTRY antimicrobial surveillance program. 1998-1999. Antimicrob. Agent Chemother. 46: 879-881.
[14]
Johnson, J., Kuskowski, M., Menard, M., Gajewski, A., Xercavins, M and Garau, J. (2006). Similarity between human and chicken
[15]
Escherichia coli isolates in relation to ciprofloxacin resistance status. Journ. Infect. Dis. 194(1): 71-78.
[16]
Kohler, N.O. (2010). Non- antibiotics Reverse Resistance of Bacteria to Antibioticsin vivo. J.Antimicrob.Chemother. 24(5):751-754.
[17]
Madigan, M., Martinko, J and Parker, J. (2003). Brock Biology of Microorganisms (10th edn). Prentice Hall, Upper Saddle River, NJ., USA. 500p.
[18]
Mbata TI (2007). Prevalence and antibiogram of UTI among prisons Inmates in Nigeria. Inter. Journ. Microbiol. 3(2):10-15.
[19]
McGowan, J.E. (2006). Resistance in non-fermenting gram negative bacteria: multidrug resistance to the maximum. American Journ. Infect. Control. 34: 29-37.
[20]
McGowan, A.P and Wise, R. (2001). Establishing MIC breakpoints and the interpretation of invitro susceptibility tests. Journ. Antimicrob. Chemother. 48: 17-28.
[21]
Mukherjee, S, Chaki, S, Das, S, Sen, S, Datta, S.K, Dastidar, S.G. (2011). Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa. Indian J. Exp.Biol. 49: 447-551.
[22]
Mukherjee, S., Chaki, S., Barman, S., Das, H., Koley and Dastidar, S.G. (2012). Effective elimination of drug resistance genes in pathogenic Pseudomonas aeruginosa by an antipsychotic agent–thioridaxine. Current Research in Bacteriology. 5:36-41.
[23]
Namita, J., Pushpa, S and Lalit, S. (2012). Control of multidrug resistant bacteria in a tertiary care hospital in India. Antimicrob. Resistance & Infection Control. 1: 23-30.
[24]
NCCLS. (2000). Methods for dilution, Antimicrobial Susceptibility Tests for bacteria that grow aerobically. Approved Standard (5th edition). Wayne, PA, USA.
[25]
Neu, H.C. (1989). Overview of mechanisms of bacterial resistance. Diagnost. Microbiol. Infect. Dis. 12: 109-116.
[26]
Obaseki-Ebor, E.E. (1984). Rifampicin curing of plasmids in Escherichia coli K12 rifampicin resistant host. Journ. Pharm. Pharmacol. 36: 467-470.
[27]
Ochei, J and Kolhhatkar, A. (2008). Medical Laboratory: Theory and practice, 10the edition. New Delhi: Tata McGraw-Hill Publishing Company. 1338p.
[28]
Okeke, I.N., Lamikanra, A and Edelman, R. (1999). Socio-economic and behavioural factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerging Infectious Diseases. 5: 18-27.
[29]
Oluremi, B.B, Idowu, A.O, Olaniyi, J.F. (2011). Antibiotic susceptibility of common bacterial pathogens in urinary tract infections in a Teaching Hospital in Southwestern Nigeria. Afr. J. Microbiol. Res. 5(22): 3658-3663.
[30]
Oskay, M., Oskay, D and Kalyoneu, F. (2009). Activity of some plant extracts against multidrug resistant human pathogens. Iranian Journ. Pharm. Research. 8(4): 293-300.
[31]
Otajevwo, F.D. (2012). Sensitivity Enhancement of Multidrug Resistant Urinary Tract Escherichia coli isolate to some commonly used Antibiotics after treatment with Non-Toxic Laboratory Concentrations of Homodium Bromide. IOSR J. Pharm. 2(3): 540-568
[32]
Otajevwo, F.D and Momoh, S.A. (2013). Resistance marker loss of multi-drug resistant (MDR) Staphylococcus aureus strains after treatment with dilutions of acridine orange. Journ. Med. & Med. Sci. 2(2):43-62. ISSN: 2241-2328.
[33]
Otajevwo, F.D and Okungbowa, A. (2014). A study on resistance loss of multidrug resistant (MDR) Pseudomonas aeruginosa strains after treatment with dilutions of acrdine orange. International Journal of Medicine & Medical Sciences. 6(1): 24-33.
[34]
Paterson, D.L and Bonomo, R. A. (2005). Extended spectrum beta-lactamase: a clinical update. Clin. Microbiol. Rev. 18(4): 657-686. DOI. 101.1128/CMR.18.4.
[35]
Reddy, G., Shridhar, P and Polasa, H. (1986). Elimination of Col. E1(pBR322 and pBR329) plasmids in Escherichia coli on treatment with hexamine ruthenium chloride. Curr. Microbiol. 13:243-246.
[36]
Salyers, A.A and Amabile-Cuevas, C.F. (1997). Why are antibiotic resistance genes so resistant to elimination? Ant. Ag. Chemo. 41(11): 2321-2325.
[37]
Shiram, V., Jahagirdar, S., Latha, C., Kumar, V., Puranik, V., Rojatkar, S. (2008). A potential plasmid curing agent, 8-epidiosbulbin E acetate
[38]
from Dioscorea bulbifera L against multidrug resistant bacteria. Int. Journ. Antimicrob. Agents. 32(5): 405-410.
[39]
Stainer, R.Y, Adelberg, E.A and Ingraham, J.L. (1984). General Microbiology, 4th edn.The Macmillan Press Ltd, Basingstoke London.
[40]
Todar, K. (2007). Pathogenic Escherichia coli in online Textbook of Bacteriology. University of Wisconsin-Madison Press. 30p
[41]
Trevors, J.T. (1986). Plasmid curing in bacteria. FEMS Microbiol. Rev. 32(3): 149-157.
[42]
Viveiros, M., Jesus, A., Brito, M., Leandro, C and Martins, M. (2010). Inducement and reversal of tetracycline resistance in Escherichia coli K12 and expression of proton gradient-dependent multidrug efflux pumps genes. Antimicrob. Agents Chemother. 49: 3578-3582.
[43]
World Health Organization. (2012). Antimicrobial resistance in the European Union and the World. Lecture delivered by Dr Margaret Chan, Director-General of W.H.O at the Conference oncombating antimicrobial resistance: time for action. Copenhagen, Denmark, March 14th, 2012.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186